Suven Pharmaceuticals (Mid Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Suven Pharmaceuticals Limited |
|||
|
Price: ₹1,185.15 | ||
| 52 Week Low: ₹585.20 52 Week High: ₹1,360.00 |
|||
| Market Capital: 16,092.32 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Suven Pharmaceuticals Share Price Target For 2024
- 1.1.1: Suven Pharmaceuticals Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Suven Pharmaceuticals Share Price Target For 2025
- 1.2.1: Suven Pharmaceuticals Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Suven Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Suven Pharmaceuticals Brief Company Overview
- 4: Suven Pharmaceuticals Financial Performance
- 4.0.1: Is Suven Pharmaceuticals A Good Buy For Long Term?
To predict the Suven Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Suven Pharmaceuticals Share Price Target For 2024
The line chart displays the monthly closing prices of Suven Pharmaceuticals with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Suven Pharmaceuticals shares in 2024, see the table below.
Suven Pharmaceuticals Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 1250.0 (+5.47%) | Price Action: 29 Oct 2024 Low |
| 2024 Target 2 | 1237.0 (+4.37%) | Price Action: 18 Dec 2024 Low |
| 2024 Target 1 | 1220.05 (+2.94%) | Price Action: 17 Dec 2024 Low |
| Current Price | 1185.15 | Suven Pharmaceuticals's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1165.56 (-1.66%) | Fibonacci Retracement Level 98.60% |
| Stop Loss 2 | 1140.09 (-3.81%) | Price Action: Oct 2024 Low |
| Stop Loss 3 | 1115.0 (-5.92%) | Price Action: Aug 2024 High |
Short-Term Technical Outlook
Current Technical Position: Suven Pharmaceuticals is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹1270.14 serves as the nearest technical reference point.
Historical Returns: 3-month: +1.04% | 6-month: +47.41% | 1-year: +63.97%
Suven Pharmaceuticals Share Price Target For 2025
The line chart displays the monthly closing prices of Suven Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Suven Pharmaceuticals shares in 2025, see the table below.
Suven Pharmaceuticals Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1747.4 (+47.44%) | Fibonacci Extension Level 150.00% |
| 2025 Target 2 | 1704.88 (+43.85%) | Price Action: Chart |
| 2025 Target 1 | 1688.0 (+42.42%) | Fibonacci Extension Level 64.90% |
| Current Price | 1185.15 | Suven Pharmaceuticals's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1064.03 (-10.22%) | Fibonacci Retracement Level 38.20% |
| Stop Loss 2 | 1042.24 (-12.06%) | Technical Indicator: MA150 |
| Stop Loss 3 | 1023.48 (-13.65%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Suven Pharmaceuticals is currently trading near its 52-week high of ₹1360, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +63.97% | 3-year: +143.71% | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Suven Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,185.15 | ||
| 2024 | ₹1,421.83 | +19.97% | ₹1,443.16 |
| 2025 | ₹2,443.99 | +71.89% | ₹2,480.65 |
| 2026 | ₹3,421.37 | +39.99% | ₹3,472.69 |
| 2027 | ₹4,383.13 | +28.11% | ₹4,448.88 |
| 2028 | ₹5,026.22 | +14.67% | ₹5,101.61 |
| 2029 | ₹6,118.57 | +21.73% | ₹6,210.35 |
| 2030 | ₹7,305.46 | +19.40% | ₹7,415.04 |
| 2031 | ₹8,290.08 | +13.48% | ₹8,414.43 |
| 2032 | ₹9,238.56 | +11.44% | ₹9,377.14 |
| 2033 | ₹9,584.21 | +3.74% | ₹9,791.24 |
| 2034 | ₹10,815.31 | +12.85% | ₹10,977.54 |
| 2035 | ₹12,166.93 | +12.50% | ₹12,349.43 |
| 2036 | ₹13,158.79 | +8.15% | ₹13,356.17 |
| 2037 | ₹14,093.99 | +7.11% | ₹14,305.40 |
| 2038 | ₹14,142.21 | +0.34% | ₹14,721.22 |
| 2039 | ₹15,290.14 | +8.12% | ₹15,953.72 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Suven Pharmaceuticals Brief Company Overview
Suven Pharmaceuticals: A Bio-Pharmaceutical Powerhouse Suven Pharmaceuticals Limited, established in 2018, is a biopharmaceutical company with a global presence. Headquartered in Hyderabad, India, Suven operates under Berhyanda Limited. Key Products and Services: New chemical...
entity-based intermediates Active pharmaceutical ingredients Specialty chemicals Formulated drugs Contract research and manufacturing services Suven's comprehensive product range caters to pharmaceutical, biotechnology, and chemical industries. Reputation and Commitment: Suven has earned a reputation for its commitment to quality and innovation. The company's diverse product offerings and global presence are a testament to its unwavering commitment to cater to the evolving needs of the industry.Suven Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 16,092.32 Crore | Market valuation of Suven Pharmaceuticals's shares. |
| Revenue (TTM) | 1,167.77 Crore | Total revenue generated by Suven Pharmaceuticals over the past twelve months. |
| Net Income (TTM) | +3,708,787,968.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +23.83% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +31.75% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-37.90% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-56.60% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
1.74 | Company's total debt divided by total shareholder equity. |
| Total Debt | 34.5 Crore | Sum of Suven Pharmaceuticals's current & long-term financial obligations. |
| Total Cash | 753.5 Crore | Total amount of liquid funds available to Suven Pharmaceuticals. |
| Beta | 1.36 | Beta is greater than 1 indicating that the Suven Pharmaceuticals's price is more volatile than the market. |
Is Suven Pharmaceuticals A Good Buy For Long Term?
Suven Pharmaceuticals, with a market cap of ₹16,092 crore, has shown mixed financial performance. While revenue has declined in the past quarter (-37.9%), the company has maintained a stable net profit margin (31.75%). Despite a significant decline in earnings compared to last year (-56.6%), its long-term returns remain positive. Considering its moderate debt and strong cash balance, Suven Pharmaceuticals could be considered as an average buy for long-term investment with moderate risk tolerance.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
